ERBB2 and breast cancer: One case (Group 5) showed differing results between the original core biopsies of the breast cancer (less than 10% HER2-positive cells by both IHC and FISH) and the metastatic disease in the lymph node (>10% HER2-positive cells by both IHC and FISH).